---
title: "Bivalirudin"
canonical_url: https://peptidelibrary.app/library/bivalirudin
description: "FDA-approved bivalent direct thrombin inhibitor used with PCI. IV bolus plus infusion per labeled weight-based regimen; hospital use only."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Bivalirudin

Bivalirudin (also called Angiomax or Hirulog) is an FDA-approved direct thrombin inhibitor. Bivalirudin is a synthetic twenty-amino-acid peptide modelled on hirudin, the anticoagulant of the medicinal leech. It is bivalent: one end occupies the catalytic site of thrombin while the other binds exosite 1, the fibrinogen recognition site, so it blocks both the enzymatic activity and the substrate docking that thrombin needs.

FDA-approved bivalent direct thrombin inhibitor used with PCI. IV bolus plus infusion per labeled weight-based regimen; hospital use only.

Also known as: Angiomax, Hirulog.

Categories: Muscle/Recovery.

## Classification

- Type: FDA-approved direct thrombin inhibitor
- Mechanism class: Direct thrombin inhibitor
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Bivalirudin is a synthetic twenty-amino-acid peptide modelled on hirudin, the anticoagulant of the medicinal leech. It is bivalent: one end occupies the catalytic site of thrombin while the other binds exosite 1, the fibrinogen recognition site, so it blocks both the enzymatic activity and the substrate docking that thrombin needs. Unlike heparin it does not require antithrombin as a cofactor and it inhibits clot-bound as well as circulating thrombin. Its action is self-limiting: thrombin slowly cleaves the bound peptide, restoring activity, which gives a short and predictable offset without a reversal agent and makes it useful where heparin-induced thrombocytopenia is a concern.

Targets: Thrombin (factor IIa).

Origin: Synthetic 20-amino-acid hirudin analog.

## Properties

- Molecular formula: C98H138N24O33
- Molecular weight: 2,180.3 g/mol
- CAS number: 128270-60-0
- Half-life: About 25 minutes with normal kidney function; longer with kidney impairment (3.5 hours in dialysis patients)
- Studied routes: Intravenous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Bivalirudin for injection (Sandoz, NDA 020873) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults undergoing PCI, including those with heparin-induced thrombocytopenia (HIT/HITTS), receiving aspirin. Anticoagulation during PCI [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce56f806-7845-429d-a1ce-c2dbf79b22eb)
2. Bivalirudin for injection (Sandoz, NDA 020873) — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Dose adjustment with anticoagulant monitoring [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ce56f806-7845-429d-a1ce-c2dbf79b22eb)

## Safety

Side effects: Bleeding; Back pain; Nausea; Hypotension.

Risks: Major hemorrhage; No reversal agent equivalent to protamine for heparin.

Human safety basis: FDA prescribing information

## Regulatory status

Bivalirudin is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Bivalirudin?

FDA-approved bivalent direct thrombin inhibitor used with PCI. IV bolus plus infusion per labeled weight-based regimen; hospital use only.

### How does Bivalirudin work?

Bivalirudin is a synthetic twenty-amino-acid peptide modelled on hirudin, the anticoagulant of the medicinal leech. It is bivalent: one end occupies the catalytic site of thrombin while the other binds exosite 1, the fibrinogen recognition site, so it blocks both the enzymatic activity and the substrate docking that thrombin needs.

### Is Bivalirudin FDA approved?

Yes. Bivalirudin is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Bivalirudin?

Reported half-life for Bivalirudin is ~25 minutes (normal renal function). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Bivalirudin banned in sport?

Bivalirudin is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Bivalirudin?

Compounds most often compared with Bivalirudin include Abaloparatide and Teriparatide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [FDA label — Angiomax](https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020873s036lbl.pdf)
- [Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation — Pediatr Crit Care Med, 2025](https://pubmed.ncbi.nlm.nih.gov/39585174/)
- [Bivalirudin in Extracorporeal Membrane Oxygenation — J Cardiovasc Pharmacol, 2024](https://pubmed.ncbi.nlm.nih.gov/39259286/)
- [Is it time to switch to bivalirudin for ECMO anticoagulation? — Front Med (Lausanne), 2023](https://pubmed.ncbi.nlm.nih.gov/37671395/)
- [Bivalirudin in pediatric extracorporeal membrane oxygenation — Curr Opin Pediatr, 2022](https://pubmed.ncbi.nlm.nih.gov/35634698/)
- [Role of Bivalirudin for Anticoagulation in Adult Perioperative Cardiothoracic Practice — J Cardiothorac Vasc Anesth, 2020](https://pubmed.ncbi.nlm.nih.gov/31521492/)

Note: Dose figures are left out of this Markdown version. See the cited sources.
